Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 712 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma November 29, 2022 Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI August 12, 2020 EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp November 24, 2020 On legacy giving: “It allows me to give something more meaningful... October 13, 2021 Load more HOT NEWS Targeting Inflammation Emerges as a Strategy for Treating Cancer FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell... Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... Tratamiento agnóstico contra el cáncer: perspectiva de un experto
